Bristol Myers Squibb Company
NEWS
Bad news for Roche Holding AG. Two of its cancer drugs, Tecentriq and taselisib, have been shown to provide only modest protection from disease progression.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
Despite the advances in personalized medicine, a new survey of 1,001 Americans shows that the majority are not familiar with the concept.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
JOBS
IN THE PRESS